Q-linea AB (publ) (QLINEA) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to Kylian's Q1 report for 2025. Appreciate everyone joining. We'll run this in the usual format. Quick disclaimer for everyone before we move on. And the topics we'll focus on today, I'll give some comments on our commercial progress that we're seeing through the quarter and some outlook for the remainder of the year and how we think about the market developing beyond that. Then I'll turn it over to Krister, who will give us a financial update and will allow for some more time this time, hopefully for questions, since the last conversation was quite engaged, which was great. We'll try to keep the upfront comments a little shorter and more emphasis on the Q&A at the end. So with that, let's jump in. The main highlight messages I'd like for everyone to take away from this quarter. Firstly, we're very pleased with the commercial progress in the quarter. It was a record one for us with five new customer contracts during the quarter. That figure surpasses, in fact, the total for the full year of 2024. So we're pleased to see that that momentum is continuing. The installations coming out of that have proceeded very smoothly. So three of those are already installed in the quarter. The remaining two are planned and will go into place shortly. And this raises the total ASTARs now in routine clinical use to seven. So the installed base continues to expand. That will in turn also drive the recurring revenues that Christa will speak to later. Overall, we're meeting the plan, both in terms of those revenues and the cost development. We now see the 20% year-on-year reduction in our operating costs. That is derived from the cost saving program last year. And that's net of some of the investments we've made into the commercial side of the organization and making sure we have...